Lv32
310 积分 2025-01-05 加入
GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction
16天前
已完结
Assessing the clinical progress of Muvalaplin for lowering lipoprotein(a)
29天前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
1个月前
已完结
How multispecific molecules are transforming pharmacotherapy
1个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
1个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
1个月前
已完结
皖公网安备34019202002308
